NCT05041907RECRUITINGanonymous

Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Sponsor

Source record

University of Oxford

Phase

Source record

PHASE2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™), Hydroxychloroquine, No treatment, Monoclonal antibodies, Fluoxetine, Molnupiravir, Sotrovimab, Ensitrelvir, Monoclonal antibodies, Favipiravir, Ivermectin, Remdesivir, Atilotrelvir/ritonavir, Metformin, Nirmatrelvir/ritonavir, Nirmatrelvir/ritonavir, Nirmatrelvir

Indication / condition

AI-normalized

COVID-19

Intervention

Source record

Related intelligence directories

Indication directory: COVID-19 Modality directory: monoclonal antibody Target directory: Nirmatrelvir/ritonavir (e.g. PAXLOVID™)

Source & freshness

Source record

NCT ID

NCT05041907

Original source

ClinicalTrials.gov

Source last updated

Feb 19, 2026

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT05041907

Title

Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Sponsor

University of Oxford

Status

RECRUITING

Phase

PHASE2

Condition raw

COVID-19

Condition normalized

COVID-19

Modality raw

COVID antiviral

Modality normalized

monoclonal antibody

Target raw

Target normalized

Interventions

Public preview

Source record

Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) is a PHASE2 clinical asset sponsored by University of Oxford in COVID-19. SEO and diligence focus: Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™), Hydroxychloroquine, No treatment, Monoclonal antibodies, Fluoxetine, Molnupiravir, Sotrovimab, Ensitrelvir, Monoclonal antibodies, Favipiravir, Ivermectin, Remdesivir, Atilotrelvir/ritonavir, Metformin, Nirmatrelvir/ritonavir, Nirmatrelvir/ritonavir, Nirmatrelvir, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT05041907

Status

RECRUITING

Phase

PHASE2

Sponsor

University of Oxford

Executive brief

Investment-Ready Snapshot

Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) is a PHASE2 clinical asset sponsored by University of Oxford in COVID-19. SEO and diligence focus: Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™), Hydroxychloroquine, No treatment, Monoclonal antibodies, Fluoxetine, Molnupiravir, Sotrovimab, Ensitrelvir, Monoclonal antibodies, Favipiravir, Ivermectin, Remdesivir, Atilotrelvir/ritonavir, Metformin, Nirmatrelvir/ritonavir, Nirmatrelvir/ritonavir, Nirmatrelvir, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedFeb 19, 2026

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05041907

Indication

COVID-19

Modality

monoclonal antibody

Target

Intervention

Source record